Heron Therapeutics (NASDAQ:HRTX) Coverage Initiated by Analysts at HC Wainwright

Analysts at HC Wainwright assumed coverage on shares of Heron Therapeutics (NASDAQ:HRTX - Get Free Report) in a report released on Monday, MarketBeat Ratings reports. The firm set a "buy" rating and a $6.00 price target on the biotechnology company's stock. HC Wainwright's target price points to a potential upside of 198.51% from the stock's previous close. HC Wainwright also issued estimates for Heron Therapeutics' Q2 2025 earnings at $0.00 EPS, Q3 2025 earnings at $0.00 EPS, Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at $0.00 EPS, FY2026 earnings at $0.04 EPS, FY2027 earnings at $0.21 EPS, FY2028 earnings at $0.43 EPS and FY2029 earnings at $0.44 EPS.

Other analysts have also issued research reports about the company. Needham & Company LLC reiterated a "buy" rating and set a $4.00 target price on shares of Heron Therapeutics in a report on Friday, April 11th. Wall Street Zen upgraded Heron Therapeutics from a "hold" rating to a "buy" rating in a research note on Friday, June 6th.

Heron Therapeutics Price Performance

Shares of HRTX traded down $0.05 during mid-day trading on Monday, hitting $2.01. 702,633 shares of the company's stock were exchanged, compared to its average volume of 2,230,790. Heron Therapeutics has a 52 week low of $1.04 and a 52 week high of $3.93. The company has a market cap of $306.65 million, a PE ratio of -11.17 and a beta of 1.16. The company has a 50-day simple moving average of $2.01 and a 200 day simple moving average of $1.88.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last released its earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.01) by $0.02. The business had revenue of $38.90 million during the quarter, compared to the consensus estimate of $37.08 million. On average, analysts anticipate that Heron Therapeutics will post -0.13 earnings per share for the current year.

Institutional Investors Weigh In On Heron Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Point72 Asset Management L.P. acquired a new position in Heron Therapeutics during the fourth quarter worth approximately $4,706,000. AIGH Capital Management LLC bought a new position in shares of Heron Therapeutics during the 1st quarter worth approximately $6,112,000. Palisade Capital Management LP boosted its stake in shares of Heron Therapeutics by 34.7% during the 1st quarter. Palisade Capital Management LP now owns 5,286,931 shares of the biotechnology company's stock worth $11,631,000 after acquiring an additional 1,360,542 shares during the period. Stonepine Capital Management LLC acquired a new position in shares of Heron Therapeutics during the 4th quarter worth approximately $1,071,000. Finally, New York State Common Retirement Fund raised its stake in Heron Therapeutics by 32.7% in the 1st quarter. New York State Common Retirement Fund now owns 1,752,924 shares of the biotechnology company's stock valued at $3,856,000 after acquiring an additional 431,918 shares during the period. 80.01% of the stock is owned by institutional investors.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.